Phase II Multicenter Trial of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens (STF-II) for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
The phase II multicenter trial of vaccination study using peptides derived from URLC10,
CDCA1, and KOC1 for locally advanced, recurrent or metastatic esophageal squamous cell
carcinoma (ESCC) who had failed for the standard therapy are performed to evaluate the
survival benefit of the cancer vaccination.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
overall survival
death from start of treatment
No
Koji Kono, PhD, MD
Principal Investigator
University of Yamanashi, First Department of Surgery
Safety and evaluation commitee, Captivation-network : JAPAN
YMU-03
NCT01267578
April 2010
May 2012
Name | Location |
---|